Cargando…

THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes

Disclosure: A. Taiwo: None. H. Thakker: None. J. Maschek: None. J. Cox: None. S. Summers: Owner/Co-Owner; Self; Centaurus Therapeutics. D. Jalal: None. W. Sivitz: None. A. Dokun: None. B. Chaurasia: None. Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by steatosis at an early...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taiwo, Adeyinka, Thakker, Himani, Maschek, John, Cox, James, Summers, Scott, Jalal, Diana, Sivitz, William, Dokun, Ayotunde, Chaurasia, Bhagirath
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Cardiovascular Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554222/ http://dx.doi.org/10.1210/jendso/bvad114.584

Ejemplares similares

THU585 Non-alcoholic Fatty Liver Disease (NAFLD), A Silent But Emerging Problem In Type 1 Diabetes
por: Taiwo, Adeyinka, et al.
Publicado: (2023)

Patients With Obesity-Related Hypertension Treated With Renin-Angiotensin-Aldosterone System Antagonists Exhibit Lower Mortality And Less Severe COVID-19: A Retrospective Study
por: Kamalumpundi, Vijayvardhan, et al.
Publicado: (2021)

SUN-078 ADAM12 Is a Direct Target of mir29a: Implications for Impaired Post-Ischemic Adaptation in Diabetes
por: Wong, Thomas, et al.
Publicado: (2019)

SUN-069 Differences in Treatment of Peripheral Arterial Disease Procedures in Hospitalized Patients with Type 1 or 2 Diabetes
por: Jain, Nidhi, et al.
Publicado: (2019)

MON-448 Detection of Thyroid Cancer Recurrence in Patients with Positive Thyroglobulin Antibody Receiving Immunoglobulin Therapy
por: Taiwo, Adeyinka, et al.
Publicado: (2020)

In a Mouse Model of Type 2 Diabetes and Peripheral Artery Disease, Modulation of MirR29a and ADAM12 Reduced Post -Ischemic Skeletal Muscle Injury, Improved Perfusion Recovery and Skeletal Muscle Function
por: Lamin, Victor, et al.
Publicado: (2021)

RF32 | PSUN44 CARF Regulates Non-Alcoholic Fatty Liver Diseases (NAFLD) by Controlling ER Stress and Lipogenesis in Hepatic Cells.
por: Friedman, Theodore, et al.
Publicado: (2022)

THU405 A Delicate Balance
por: Mohan, Nikita, et al.
Publicado: (2023)

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
por: Rong, Li, et al.
Publicado: (2023)

Diabetes mellitus in peripheral artery disease: Beyond a risk factor
por: Singh, Madhu V., et al.
Publicado: (2023)

THU601 Massive Pericardial Effusion As Sole Symptom For Uncontrolled Hypothyroidism.
por: Lopez, David A, et al.
Publicado: (2023)

THU642 Progression To Cirrhosis And All-cause Mortality Are Increased In Postmenopausal Women With NAFLD
por: Izzi-Engbeaya, Chioma, et al.
Publicado: (2023)

THU597 Po(2)-guided Adrenal Vein Sampling In Primary Aldosteronism
por: Omata, Kei, et al.
Publicado: (2023)

THU583 Cardioprotection By Nitric Oxide Is Mediated Via Mitochondrial Function In Rodents
por: Islam, Kazi, et al.
Publicado: (2023)

Clinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity
por: Barbieri, Emiliano, et al.
Publicado: (2023)

THU590 Screening Of Primary Aldosteronism With Low-threshold Criteria In An Outpatient Clinic Setting
por: Mon Myint, Myat Su, et al.
Publicado: (2023)

THU598 Pseudohypoaldosteronism Type 2: A New Variant Of A Rare Disease
por: Gray Cater, Taylor Lauren, et al.
Publicado: (2023)

THU596 Heteromerization Of The Angiotensin II Type 1 Receptor And The Bradykinin Type 2 Receptor
por: Johnstone, Elizabeth K M, et al.
Publicado: (2023)

THU599 Serum And Urinary Free Cortisone As Novel Predictor Of Low-renin Arterial Hypertension
por: Tapia-Castillo, Alejandra, et al.
Publicado: (2023)

THU593 Unilaterally Selective Adrenal Vein Sampling For Identification Of Surgically Curable Primary Aldosteronism
por: Paolo Rossi, Gian, et al.
Publicado: (2023)

THU589 Positivity Rates Of Screening Criteria For Primary Aldosteronism: A Cohort Comparison Study
por: Marcelli, Marco, et al.
Publicado: (2023)

THU588 Sparing Confirmatory Testing In Primary Aldosteronism: The Combination Of Renin, Aldosterone And Potassium Levels
por: Chua Ong Lopez, Albert Macaire, et al.
Publicado: (2023)

Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)
por: Cuthbertson, Daniel J., et al.
Publicado: (2021)

Editorial: The roles and mechanisms of hepatokines, adipokines and myokines in the development of non-alcoholic fatty liver disease (NAFLD)
por: Lu, Yan
Publicado: (2022)

OR02-1 Differences in HDL Particle Composition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) and Advanced Liver Fibrosis May Explain Higher Cardiovascular Risk
por: Collier, Timothy, et al.
Publicado: (2022)

THU584 Comparison Of The Cardiovascular Benefits Of Bempedoic Acid With Statins- Analysis By The Cholesterol Treatment Trialists’ Methodology
por: Lincoff, A Michael, et al.
Publicado: (2023)

THU582 Actionable Circulating Proteins Mediate The Effect Of Obesity On Cardiometabolic Diseases: An Integrative Proteogenomics Analysis
por: Yoshiji, Satoshi, et al.
Publicado: (2023)

THU333 Race Was Not A Predictor Of Poor Outcomes From COVID-19 At University Of Chicago Medicine Hospital
por: Rashied, Ammar, et al.
Publicado: (2023)

THU591 HyperAldosteronism In Pregnancy Predicted Impacts (H.A.P.P.I.): A Retrospective Cohort Study
por: Oprea, Diana, et al.
Publicado: (2023)

THU600 Coronary Calcium Scores In Medical Group Versus Individualized Dietitian-led Visits Group In An Inner-city Setting
por: Friedman, Theodore C, et al.
Publicado: (2023)

THU587 High Prevalence Of Primary Aldosteronism Diagnosis In Patients With Papillary Thyroid Cancer And Hypertension: A Cross-sectional Case-control Study
por: Ana Wolf, Ana Alice Wolf Maciel, et al.
Publicado: (2023)

THU595 New Screening Cutoff Values For Detection Of Aldosterone Producing Adenoma Examined By LC-MS/MS And Newly Developed Non-competitive Cleia
por: Satoh, Fumitoshi, et al.
Publicado: (2023)

Identification of biomarkers for the diagnosis of chronic kidney disease (CKD) with non-alcoholic fatty liver disease (NAFLD) by bioinformatics analysis and machine learning
por: Cao, Yang, et al.
Publicado: (2023)

SAT-088 A Novel Mutation In The Leptin Receptor Associated With Hypertriglyceridemia, Lipodystrophy And Non-alcoholic Fatty Liver
por: Viana, Gracia, et al.
Publicado: (2019)

Genome-Wide Meta-Analysis and Mendelian Randomization Identify Early Biomarkers of Non-Alcoholic Fatty Liver Disease
por: Gobeil, Emilie, et al.
Publicado: (2021)

Ceramides in Adipose Tissue
por: Li, Ying, et al.
Publicado: (2020)

Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
por: Jeong, Seogsong, et al.
Publicado: (2023)

CARF (CDKN2AIP) Regulates Hepatic Lipid Metabolism and Protects Against Development of Non-Alcoholic Fatty Liver Diseases
por: Hasan, Kamrul M, et al.
Publicado: (2021)

THU594 Outcome Data From Fabulas: A Feasibility Study Of Radiofrequency Endoscopic Ablation, With Ultrasound Guidance, As A Non-surgical, Adrenal Sparing Treatment For Aldosterone Producing Adenomas
por: Argentesi, Giulia, et al.
Publicado: (2023)

The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC)
por: Venniyoor, Ajit, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m09a6sgsspck5cbbu68p67htib